Instrument Fundamentals
Date | Close | Change | Change (%) | Open | High | Low |
---|
News
New HIV prevention drug could reach poorest countries by 2025, says health official | The Star
Gilead Sciences CFO sells $781,660 in stock By Investing.com
FDA grants breakthrough status to Gilead's lung cancer drug By Investing.com
Gilead Sciences, Terray Therapeutics Set AI-Powered Research Collaboration | Morningstar
FDA Grants Breakthrough Therapy Status To Gilead's Trodelvy For Treatment Of Small Cell Lung Cancer
Gilead Inks Strategic Collaboration With Terray Therapeutics To Develop Small Molecule Therapies
B. Riley Wealth Advisors Inc. Sells 15,668 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)
New HIV prevention drug could reach poorest countries by 2025, says health official By Reuters
Bernstein remains bullish on Gilead stock, sees leadership strengthening future growth By Investing.com
Gilead partners with Terray for AI-driven drug discovery By Investing.com
Gilead Sciences, Inc. (NASDAQ:GILD) Sees Large Increase in Short Interest
Gilead (GILD) Upgraded to Buy: Here's Why - December 16, 2024 - Zacks.com
GILD Obtains Positive CHMP Opinion for Liver Disease Drug - December 16, 2024 - Zacks.com
Roche Gets Approval for Vabysmo PFS in EU for Three Retinal Diseases - December 16, 2024 - Zacks.com
Gilead Sciences' SWOT analysis: lenacapavir success fuels HIV stock growth By Investing.com
Gilead Sciences, Inc. (NASDAQ:GILD) Shares Purchased by Franklin Resources Inc.
Gilead Sciences, Inc. (NASDAQ:GILD) Shares Acquired by Synovus Financial Corp
Wilmington Savings Fund Society FSB Has $1.56 Million Position in Gilead Sciences, Inc. (NASDAQ:GILD)
Gilead Sciences, Inc. (NASDAQ:GILD) Receives Average Recommendation of "Moderate Buy" from Brokerages
DGS Capital Management LLC Sells 1,492 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)
DGS Capital Management LLC Has $300,000 Position in Gilead Sciences, Inc. (NASDAQ:GILD)
50,000 Shares in Gilead Sciences, Inc. (NASDAQ:GILD) Bought by Exome Asset Management LLC
2,495 Shares in Gilead Sciences, Inc. (NASDAQ:GILD) Purchased by Pine Valley Investments Ltd Liability Co
2,883 Shares in Gilead Sciences, Inc. (NASDAQ:GILD) Acquired by Brass Tax Wealth Management Inc.
Retirement Systems of Alabama Cuts Stake in Gilead Sciences, Inc. (NASDAQ:GILD)
Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by American Trust
Tri Ri Asset Management Corp Buys Shares of 40,314 Gilead Sciences, Inc. (NASDAQ:GILD)
Gilead Sciences, Inc. (NASDAQ:GILD) Shares Purchased by Tidal Investments LLC
Gilead Gets Key European Backing for Liver-Disease Treatment | Morningstar
Gilead Sciences, Inc. (NASDAQ:GILD) Stock Position Lifted by Sanctuary Advisors LLC
Gilead Sciences Says Seladelpar Gets Positive CHMP Opinion For Primary Biliary Cholangitis
Leerink Partnrs Lifts Earnings Estimates for Gilead Sciences
Gilead’s Seladelpar Receives Positive CHMP Opinion for Primary Biliary Cholangitis | Morningstar
Gilead Sciences, Inc. (NASDAQ:GILD) Position Trimmed by TCW Group Inc.
Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Teachers Retirement System of The State of Kentucky
XTX Topco Ltd Takes Position in Gilead Sciences, Inc. (NASDAQ:GILD)
Gilead Sciences: Gilead appoints Sanofi official Dietmar Berger as next chief medical officer, ETPharma
Seladelpar wins CHMP endorsement for rare liver disease By Investing.com
Gilead Sciences (GILD) Stock Moves -0.57%: What You Should Know - December 13, 2024 - Zacks.com
Stock Traders Purchase Large Volume of Call Options on Gilead Sciences (NASDAQ:GILD)
SkyView Investment Advisors LLC Purchases 435 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)
Blankinship & Foster LLC Takes $1.01 Million Position in Gilead Sciences, Inc. (NASDAQ:GILD)
Gilead appoints Sanofi official Dietmar Berger as next chief medical officer By Reuters
Arvest Bank Trust Division Takes Position in Gilead Sciences, Inc. (NASDAQ:GILD)
Te Ahumairangi Investment Management Ltd Sells 9,587 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)
Zacks Research Forecasts Higher Earnings for Gilead Sciences
Tri Ri Asset Management Corp Takes Position in Gilead Sciences, Inc. (NASDAQ:GILD)
TD Private Client Wealth LLC Increases Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)
Toronto Dominion Bank Trims Stake in Gilead Sciences, Inc. (NASDAQ:GILD)
Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It - December 12, 2024 - Zacks.com
Is Gilead Sciences (GILD) Stock Undervalued Right Now? - December 12, 2024 - Zacks.com
CADL Stock Soars as Phase III Prostate Cancer Study Meets Primary Goal - December 12, 2024 - Zacks.com
Gilead Sciences’ (GILD) “Neutral” Rating Reiterated at Cantor Fitzgerald
Macy's gives update on employee who hid $151M
Gilead Sciences, Inc. (GILD) To Go Ex-Dividend on December 13th
Gilead stock outlook hinges on Lenacapavir's PrEP launch and untapped patient expansion, says DB By Investing.com
TT International Asset Management LTD Invests $1.26 Million in Gilead Sciences, Inc. (NASDAQ:GILD)
LRI Investments LLC Boosts Position in Gilead Sciences, Inc. (NASDAQ:GILD)
M&T Bank Corp Has $16.18 Million Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)
This pharma stock could easily gain 20% next year, Jefferies says By Investing.com
CRDF Stock Soars on Robust Efficacy Data From Colorectal Cancer Study - December 11, 2024 - Zacks.com
QURE Soars on FDA Alignment for Speedy Approval of Huntington's Drug - December 11, 2024 - Zacks.com
Vestcor Inc Reduces Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)
Oppenheimer Forecasts Strong Price Appreciation for Gilead Sciences (NASDAQ:GILD) Stock
Gilead Sciences (NASDAQ:GILD) Given "Buy" Rating at Bank of America
15,203 Shares in Gilead Sciences, Inc. (NASDAQ:GILD) Purchased by Brophy Wealth Management LLC
Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Vestcor Inc
Groupama Asset Managment Acquires 24,956 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)
Gilead Sciences, Inc. (NASDAQ:GILD) Shares Bought by MML Investors Services LLC
The Zacks Analyst Blog Highlights Eli Lilly, AbbVie, Gilead Sciences, Air T and Fossil Group
KOD Stock Up as Jefferies Upgrades Rating on Huge Pipeline Potential - December 10, 2024 - Zacks.com
Longest Follow-Up Data Reported for Kite’s Tecartus® CAR T-Cell Therapy at ASH 2024 Reinforce Durable Efficacy and Survival Benefits
Gilead Sciences : Longest Follow-Up Data Reported for Kite’s Tecartus CAR T-Cell Therapy at ASH 2024 Reinforce Durable Efficacy and Survival Benefits By Investing.com
Abel Hall LLC Cuts Position in Gilead Sciences, Inc. (NASDAQ:GILD)
Nomura Asset Management Co. Ltd. Sells 97,655 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)
Top Stock Reports for Eli Lilly, AbbVie & Gilead Sciences
FDA Accepts GSK's Filing for Expanded Use of Nucala in COPD - December 9, 2024 - Zacks.com
Gilead Sciences, Inc. (NASDAQ:GILD) Shares Acquired by Zurich Insurance Group Ltd FI
Gilead Sciences, Inc. (NASDAQ:GILD) Shares Bought by Kovitz Investment Group Partners LLC
Weiss Asset Management LP Invests $1.68 Million in Gilead Sciences, Inc. (NASDAQ:GILD)
7 Stocks That May Provide the Real Solution to The Coronavirus Puzzle
Zacks Investment Management Acquires 33,099 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)
National Bank of Canada FI Cuts Stake in Gilead Sciences, Inc. (NASDAQ:GILD)
Gilead Sciences, Inc. (NASDAQ:GILD) Shares Acquired by Quantinno Capital Management LP
Two Sigma Advisers LP Has $208.58 Million Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)
Gilead Sciences, Inc. (NASDAQ:GILD) Position Decreased by Sarissa Capital Management LP
Gilead Sciences, Inc. (NASDAQ:GILD) is Sarissa Capital Management LP's 3rd Largest Position
Janus Henderson Group PLC Has $147.69 Million Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)
Hilltop Holdings Inc. Increases Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)